<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="462">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315298</url>
  </required_header>
  <id_info>
    <org_study_id>6R88-COV-2040</org_study_id>
    <nct_id>NCT04315298</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19</brief_title>
  <official_title>An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2:

      The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative
      to the control arm in adult patients hospitalized with COVID-19 regardless of disease
      severity strata.

      Phase 3 Cohort 1:

      The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative
      to the control arm in adult patients hospitalized with critical COVID-19 receiving mechanical
      ventilation at baseline.

      Phase 3 Cohort 2:

      The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative
      to the control arm in adult patients hospitalized with COVID-19 receiving mechanical
      ventilation at baseline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2020</start_date>
  <completion_date type="Actual">September 2, 2020</completion_date>
  <primary_completion_date type="Actual">July 24, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in C-reactive protein (CRP) levels in patients with serum IL-6 level greater than the upper limit of normal</measure>
    <time_frame>Day 4</time_frame>
    <description>Phase 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with critical COVID-19 receiving mechanical ventilation at baseline</measure>
    <time_frame>Up to day 22</time_frame>
    <description>Phase 3 Cohort 1
7-point Ordinal Scale:
Death;
Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);
Hospitalized, requiring non-invasive ventilation or high flow oxygen devices;
Hospitalized, requiring supplemental oxygen;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care
Not hospitalized</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with COVID-19 receiving mechanical ventilation at baseline</measure>
    <time_frame>Up to day 22</time_frame>
    <description>Phase 3 Cohort 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2
Resolution of fever defined as postbaseline body temperature &lt;37.2°C (oral), or &lt;37.6°C (rectal or tympanic) or &lt;36.8°C (temporal or axillary)
Documented fever defined as ≥38°C (oral), ≥38.4°C (rectal or tympanic), or ≥37.6°C (temporal or axillary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever for at least 48 hours without antipyretics by clinical severity</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2
Defined as postbaseline body temperature &lt;37.2°C (oral), or &lt;37.6°C (rectal or tympanic) or &lt;36.8°C (temporal or axillary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2
Defined as postbaseline body temperature &lt;37.2°C (oral), or &lt;37.6°C (rectal or tympanic) or &lt;36.8°C (temporal or axillary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement in oxygenation for at least 48 hours</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2
Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement in oxygenation for at least 48 hours by clinical severity</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2
Defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2
Defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever and improvement in oxygenation for at least 48 hours</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2
Resolution of fever defined as postbaseline body temperature &lt;37.2°C (oral), or &lt;37.6°C (rectal or tympanic) or &lt;36.8°C (temporal or axillary)
Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the 7-point ordinal scale</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients in each clinical status category using the 7-point ordinal scale</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2
NEWS2 consists of: Physiological Parameters: Respiration rate (per minute), SpO2 Scale 1 (%), SpO2 Scale 2 (%), Use of Air or oxygen, Systolic blood pressure (mmHg), Pulse (per minute), Consciousness, Temperature (°C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NEWS2 scoring system</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with fever</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2
Defined as ≥38°C (oral), ≥38.4°C (rectal or tympanic) or ≥37.6°C (temporal or axillary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive, off oxygen</measure>
    <time_frame>At day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of resting respiratory rate &gt;24 breaths/min</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with hypoxemia</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of supplemental oxygen use</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to saturation ≥94% on room air</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilator free days in the first 28 days</measure>
    <time_frame>Baseline to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring initiation of mechanical ventilation</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring non-invasive ventilation</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring the use of high flow nasal cannula</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients admitted into an intensive care unit (ICU)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospitalization among survivors</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths due to any cause</measure>
    <time_frame>Up to day 60</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale</measure>
    <time_frame>Up to day 22</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who recover</measure>
    <time_frame>Up to day 22</time_frame>
    <description>Phase 3
Defined as discharged, or alive without supplemental oxygen use or at pre-COVID oxygen use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of deaths</measure>
    <time_frame>Through day 29</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive not receiving mechanical ventilation</measure>
    <time_frame>At day 22</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients alive not requiring extracorporeal membrane oxygenation (ECMO)</measure>
    <time_frame>At day 22</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a 2-point improvement in clinical status on the 7-point ordinal scale</measure>
    <time_frame>Up to day 22</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to at least 1-point improvement in clinical status assessment on the 7-point ordinal scale</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to at least 2-point improvement in clinical status assessment on the 7-point ordinal scale</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients receiving mechanical ventilation</measure>
    <time_frame>Up to day 22</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients receiving ECMO</measure>
    <time_frame>Up to day 22</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients discharged and alive</measure>
    <time_frame>At day 22</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 3
Defined as discharged or alive without supplemental oxygen use or at pre-COVID oxygen use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of deaths</measure>
    <time_frame>Through day 60</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death due to any cause</measure>
    <time_frame>Through day 60</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilator free days</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospitalization among survivors</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with serious adverse events</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Grade 4 neutropenia (ANC &lt;500/mm3)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia (ANC &lt;500/mm3)</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with hypersensitivity reactions</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with infusion reactions</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with gastrointestinal perforation</measure>
    <time_frame>Up to day 29</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell count</measure>
    <time_frame>Up to day 29 if still hospitalized</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin levels</measure>
    <time_frame>Up to day 29 if still hospitalized</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>Up to day 29 if still hospitalized</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine levels</measure>
    <time_frame>Up to day 29 if still hospitalized</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bilirubin level</measure>
    <time_frame>Up to day 29 if still hospitalized</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase (ALT) level</measure>
    <time_frame>Up to day 29 if still hospitalized</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase (AST) level</measure>
    <time_frame>Up to day 29 if still hospitalized</time_frame>
    <description>Phase 2 and Phase 3</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1912</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Sarilumab low dose (P2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab low dose (P3:C1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 3: Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab mid dose (P2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab mid dose (P3:C1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 3: Cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab high dose (P3:C2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 3: Cohort 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarilumab</intervention_name>
    <description>Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.</description>
    <arm_group_label>Sarilumab high dose (P3:C2)</arm_group_label>
    <arm_group_label>Sarilumab low dose (P2)</arm_group_label>
    <arm_group_label>Sarilumab low dose (P3:C1)</arm_group_label>
    <arm_group_label>Sarilumab mid dose (P2)</arm_group_label>
    <arm_group_label>Sarilumab mid dose (P3:C1)</arm_group_label>
    <other_name>Kevzara®</other_name>
    <other_name>REGN88</other_name>
    <other_name>SAR153191</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single or multiple intravenous (IV) doses of placebo to match sarilumab administration</description>
    <arm_group_label>Sarilumab high dose (P3:C2)</arm_group_label>
    <arm_group_label>Sarilumab low dose (P2)</arm_group_label>
    <arm_group_label>Sarilumab low dose (P3:C1)</arm_group_label>
    <arm_group_label>Sarilumab mid dose (P2)</arm_group_label>
    <arm_group_label>Sarilumab mid dose (P3:C1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction
             (PCR), result from any specimen (or other commercial or public health assay) within 2
             weeks prior to randomization and no alternative explanation for current clinical
             condition

          -  Hospitalized with illness of any duration with evidence of pneumonia, requires
             supplemental oxygen and/or assisted ventilation and meets one of the following:

          -  Phase 2 and Phase 3 Cohort 1:

        Meets 1 of the following criteria at baseline:

          -  Severe disease or

          -  Critical disease or

          -  Multi-system organ dysfunction or

          -  Immunocompromised

          -  Phase 3 Cohort 2:

        Patients must be receiving mechanical ventilation to treat respiratory failure due to
        COVID-19

          -  Ability to provide informed consent signed by study patient or legally acceptable
             representative

          -  Willingness and ability to comply with study-related procedures/assessments

        Key Exclusion Criteria:

          -  In the opinion of the investigator, not expected to survive for more than 48 hours
             from screening

          -  Presence of any of the following abnormal laboratory values at screening: absolute
             neutrophil count (ANC) less than 2000 mm3, aspartate aminotransferase (AST) or alanine
             aminotransferase (ALT) &gt; 5 x upper limit of normal (ULN), platelets &lt;50,000 per mm3

          -  Treatment with anti-IL 6, anti-IL-6R antagonists, or with Janus kinase inhibitors
             (JAKi) in the past 30 days or plans to receive during the study period

          -  Current treatment with the simultaneous combination of leflunomide and methotrexate

          -  Known active tuberculosis (TB), history of incompletely treated TB, suspected or known
             extrapulmonary TB, suspected or known systemic bacterial or fungal infections

          -  Participation in a double-blind clinical research study evaluating an investigational
             product (IP) or therapy within 3 months and less than 5 half-lives of IP prior to the
             screening visit (The use of remdesivir, hydroxychloroquine, or other treatments being
             used for COVID-19 treatments in the context of an open-label study, Emergency Use
             Authorization (EUA), compassionate use protocol or open-label use is permitted)

          -  Any physical examination findings, and/or history of any illness, concomitant
             medications or recent live vaccines that, in the opinion of the study investigator,
             might confound the results of the study or pose an additional risk to the patient by
             their participation in the study

          -  Known systemic hypersensitivity to sarilumab or the excipients of the drug product

          -  Phase 3 Cohort 2 only:

          -  Known or suspected history of immunosuppression or immunodeficiency disorder

          -  Patients who require renal replacement therapy for acute kidney injury at
             randomization or who required renal replacement therapy within 72 hours prior to
             randomization

          -  Patients who have circulatory shock requiring vasopressors at randomization or within
             24 hours prior to randomization

          -  Use of extracorporeal life support (eg, ECMO) or, in the opinion of the investigator,
             there is a high likelihood that extracorporeal life support will be initiated within
             48 hours after randomization

        NOTE: Other protocol defined inclusion / exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 1</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 2</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Elmhurst</city>
        <state>New York</state>
        <zip>11373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 1</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 2</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 1</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site 2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Scranton</city>
        <state>Pennsylvania</state>
        <zip>18510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 15, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>coronavirus</keyword>
  <keyword>IL-6</keyword>
  <keyword>sarilumab</keyword>
  <keyword>acute respiratory distress syndrome</keyword>
  <keyword>treatment</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

